Public release date: 18-Mar-2013 [ | E-mail | Share ]

Contact: Shawna Williams shawna@jhmi.edu 410-955-8236 Johns Hopkins Medicine

A new online database combining symptoms, family history and genetic sequencing information is speeding the search for diseases caused by a single rogue gene. As described in an article in the May issue of Human Mutation, the database, known as PhenoDB, enables any clinician to document cases of unusual genetic diseases for analysis by researchers at the Johns Hopkins University School of Medicine or the Baylor College of Medicine in Houston. If a review committee agrees that the patient may indeed have a previously unknown genetic disease, the patient and some of his or her family members may be offered free comprehensive genetic testing in an effort to identify the disease culprit.

"PhenoDB is much more useful than I even thought it would be," says Ada Hamosh, M.D., M.P.H., a professor in the McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine. "Bringing all of this information together is crucial to figuring out what our genetic variations mean." The database is designed to capture a bevy of standardized information about phenotype, which Hamosh defines as "any characteristic of a person" symptoms, personal and family health history, appearance, etc.

Hamosh and others developed PhenoDB for the Baylor-Hopkins Center for Mendelian Genomics (BHCMG), a four-year initiative that, together with its counterparts at Yale University and the University of Washington, is charged with uncovering the genetic roots of every disorder caused by a single faulty gene. There are an estimated 3,000 inherited disorders that have been described phenotypically in scientific papers but whose genetic causes have not yet been pinpointed, Hamosh says, but since many single-gene disorders are extremely rare, she suspects that many more have not yet made it into the literature.

The Centers for Mendelian Genomics have a powerful tool at their disposal, known as whole-exome sequencing. Just a few years ago, Hamosh explains, a geneticist trying to diagnose the cause of an inherited disease would have made an educated guess based on the patient's signs and symptoms about which gene might be at fault, and ordered a test of that gene. If the test came back negative for a mutation, she would order a test of a different gene, and so on. But whole-exome sequencing, in which about 90% of a person's genes are sequenced at one time, has been growing steadily cheaper, and it is this tool that the Centers will use to capture genetic sequencing information (whole-genome sequencing is the next step, but it remains too expensive for many uses, Hamosh notes, as it includes all of a person's DNA, most of which contains no genes).

However, making sense of the deluge of data yielded by whole-exome sequencing presents its own challenges. "The average person has tens of thousands of variations from the standard genetic sequence," Hamosh explains, "and we don't know what most of those variations mean." To parse these variations, she says, "one of the things that needs to change is that the lab doing the testing needs to have the whole phenotype, from head to toe." Researchers will then be better equipped to figure out which variations may or may not be relevant to a patient's illness. Another advantage of the database is that it enables colleagues at distant locations such as Baylor and Johns Hopkins to securely access the information and collaborate. Hamosh notes that the database enables different users to be afforded different levels of access for example, a health provider will only be able to see the information he or she has entered and that information is deidentified to protect patient privacy. In addition, providers must have patients' consent to be included in PhenoDB.

PhenoDB would be useful for any research project that seeks to match genomic information with its phenotypic effects, Hamosh says, and with that in mind, the Baylor-Hopkins Center for Mendelian Genomics has made the PhenoDB software available for free download at http://phenodb.net. She predicts that similar tools will soon be incorporated into electronic health records as well, so that "doctors will have patients' genomic information at their fingertips and can combine that with information about health history, disease symptoms and social situation to practice truly individualized medicine."

###

Other authors on the paper are Nara Sobreira, Julie Hoover-Fong, Corinne Boehm and David Valle, all of the Johns Hopkins University School of Medicine; V. Reid Sutton of Baylor College of Medicine; and Franois Schiettecatte of FS Consulting.

Go here to see the original:
New database to speed genetic discoveries

Recommendation and review posted by Bethany Smith

FIVE POINTS, Calif., March 18, 2013 /PRNewswire/ -- S&W Seed Company (SANW) announced, through a press release issued on Sunday, March 17th, that it has agreedtopurchase 100% ofSeed Genetics InternationalPty Ltd("SGI"), subject to due diligence and other customary conditions.The combination of S&W with Adelaide, Australia-based SGI will create the world 's largest non-dormant alfalfa seed company. The transaction, which is valued at approximately $16 million, is scheduled to close in early April 2013 and is expected to be immediately accretive to S&W's earnings.

Mark Grewal, president and chief executive officer of S&W Seed Company, commented, "This pact creates a powerhouse that will be unrivaled in its ability to breed and produce non-dormant alfalfa seed all year round.SGI has a tremendous base of contracted growers, very strong customer relationships, andunique genetics.The sales channels that S&W and SGI sell into are highly complementary,with very little overlap in customers. This move considerably strengthens our reach into Argentina and the rest of Latin America."

Grewal added, "I also want to stress the 'people factor.'S&W is gaining a highly competitive team of veteran seedsmen whom we know well and highly respect. We look forward to collaboration with them in all areas. By putting growers first, SGI's breeding program, initiated by Dr. Ross Downes and now continued by David Pengelly, has created grower-focused varieties that produce more seed per acre for the seed farmer than any other varieties in Australia, adding to seed farmer profits and potentially lowering cost of seed for S&W. We have the opportunity to merge David's work with that of S&W's own VP of Genetics and Breeding, Dan Gardner and our emeritus breeder,Bob Sheesley, who himself did pioneering work in salt tolerance and seed yield."

S&W is paying a purchase price ofapproximately $16million, over half of which consists of 865,000 shares S&W Common Stock and will result in SGI's owners becoming significant shareholders of S&W. The remaining considerationconsists of $5million in cash and$3million in the form of athree-yearpromissory note.Based on unaudited information, SGI hadrevenues of approximately AUD $18million for the fiscal year ended June 30, 2012 andhadpre-tax income of$1.6 million. SGI's assets consist primarily of accounts receivable, inventory, a tenured grower base and intellectual property, such as genetics.S&W intends to file audited financial resultsofSGIno later than 74 daysfrom closing,in compliance with SEC guidelines.

SGIcontrols approximately17,000 acres of irrigated alfalfa seed production under contract, and has first call on another 12,000acres of non-irrigated land that is rain dependent and has intermittent production. Australian seed yields per acre, even on irrigated fields, typically are materially lower than S&W's California yields and production costs are also materially lower.In 2013, SGIcontracted for alfalfa seed production with approximately 140contractfarmersin Southern Australia, all for SGI's proprietary varieties.In fiscal 2012, SGI's growers producedapproximately 5.5 million pounds, concluding a growing season that suffered from the impact of highly adverse weather conditions. The 2013 harvest is currently ongoing, but based on initial estimates, SGI managementis estimating that it will have approximately 8million pounds of alfalfa seed available for sale when the harvest concludes in late April 2013. Actual production could vary materially in either direction from estimates, due to unforeseen weather events and other factors.

SGIsells intointernational markets, includingthe Middle East and Africa (MENA), South America, and Southern Europe with the majority of the company's sales concentrated in the April through September time frame.

SGI was founded in 2002, with the goal of commercializing a seed breeding breakthrough by Dr. Ross Downes. Working with alfalfa in the mid 1990's, Dr. Downes had identified a particular trait that resulted in dramatically increased seed yields, even with less than optimum pollinator activity. The intellectual property stemming from Dr. Downes' pioneering work, which has been protected under international law and the Australian Plant Breeders Rights Act, became the cornerstone for over a decade of development by SGI's David Pengelly. SGI has developed well known proprietary varieties, such asSuperSonic, SuperNova, SuperStar, SuperCharge, SuperAurora, SuperSequal and SuperSiriver. Starting in 2002, the varieties developed by SGI quickly attracted a grower base that by 2012 enabled SGIto exceed 60%of Australian alfalfa seed production.SGI'salfalfa seed varieties are bred to resist disease, have tolerance to salt, create persistence in the field, and produce high seed yields in Australian production.The company also has a number of developments within its breeding program pertaining to dormant alfalfa varieties, tropical alfalfa seed varieties, and ease of pollination.

SGI, like S&W, considers the goodwill of its seed grower base to be of premier importance. SGI's contracts with seedfarmers under long term contracts that typically have initial terms of six years, extendable to ten years. To manage risk for itself and its growers, seed pricing is not fixed by contract, but instead based upon pooled production which is sold over an entire season, with a view to optimizing the prices realized. Due to its Southern Hemisphere location,SGIharvests seed in March through April, which is counter cyclical to S&W's July through October production in the Northern Hemisphere. The combined company will have the competitive advantages of year round production, which extends to all areas of the alfalfa seed business, including sales, inventory management and cash collection cycles.

Mark Harvey,Directorof Seed Genetics International, commented, "First, my thanks to S&W's Chairman, Grover Wickersham, and S&W's CFO, Matt Szot, for their long visits to Australia and their patience in negotiating over the last half year. While this is obviously a big move for us, the directors and management of SGI are trulyexcited about the advantages of a combined S&W/SGI and we want the challenge of continuing to build on what the four partners started."

Mr. Harvey expanded, "For our Australian growers, this means we willbeexpanding production under the umbrella of a public company with a strong balance sheet and financial resources. We also gain access to S&W's proven proprietary genetics. We look forward to collaborating with S&W's well respected breeder, Dan Gardner, who is well known by our own David Pengelly and Ross Downes. When we learned last year that Dan and our tough and respected sales and marketing competitor from IVS, Fred Fabre, had both joined S&W, it piqued ourinterest."

More:
Investor Advisory: S&W Seed Company To Acquire Seed Genetics International

Recommendation and review posted by Bethany Smith

Seattle Genetics, Inc. (SGEN) recently announced the submission of a supplemental biologics license application (sBLA) to the US Food and Drug Administration (:FDA) for the use of Adcetris (brentuximab vedotin) in the retreatment of patients and for extended duration of use beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).

The sBLA was based on results from a phase II study. The study had two treatment arms. One arm evaluated retreatment with Adcetris in patients who had responded to Adcetris treatment earlier, then discontinued treatment and as a result suffered disease progression or relapse. The other arm evaluated prolonged treatment with Adcetris beyond 16 cycles of therapy.

Adcetris was approved by the FDA in Aug 2011 for the treatment of patients with HL after failure of autologous stem cell transplant (:ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris was also approved for sALCL in treatment-experienced patients. In Oct 2012, Adcetris gained EU approval as well for the same indications.

In Jan 2013, a global phase III study (ECHELON-2) was initiated on Adcetris. In this study, Adcetris plus chemotherapy will be evaluated for the front-line treatment of CD30-positive mature T-cell lymphoma (:MTCL) including patients with sALCL and other types of peripheral T-cell lymphomas.

In Feb 2013, Adcetris received approval under Health Canada's Notice of Compliance with conditions (NOC/c) for the treatment of relapsed or refractory HL and sALCL.

Our Take

We are positive on Seattle Genetics efforts to expand Adcetris label. Adcetris net product revenue in the fourth quarter of 2012 was $35.4 million.

Seattle Genetics carries a Zacks Rank #3 (Hold). Right now, Cytokinetics, Inc. (CYTK), Osiris Therapeutics, Inc. (OSIR), and XOMA Corporation (XOMA) look more attractive with a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on OSIR

Read the Full Research Report on XOMA

See more here:
SGEN Seeks Adcetris Label Expansion

Recommendation and review posted by Bethany Smith

Seattle Genetics has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration supporting the use of ADCETRIS for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL. The sBLA is based on results from a phase II clinical trial with two treatment arms. One arm evaluated retreatment with ADCETRIS in patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse. The other arm allowed treatment extension and evaluated prolonged treatment with ADCETRIS beyond 16 cycles of therapy. The sBLA submission includes updated data sets from this phase II trial. Preliminary data from this trial were previously reported at the 2011 American Society of Hematology Annual Meeting and at the 2012 American Society of Clinical Oncology Annual meeting.

Go here to see the original:
Seattle Genetics submits sBLA to FDA for ADCETRIS

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL.

The sBLA submission includes data demonstrating ADCETRIS activity in managing HL and sALCL when used in the retreatment setting, as well as beyond the 16 cycles described in our current label, while retaining a manageable safety profile, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Our goal is to broaden the ADCETRIS U.S. labeling claims to provide both patients and physicians the opportunity to incorporate ADCETRIS into additional HL and sALCL treatment settings. The sBLA submission includes data that support these uses and we look forward to the regulatory outcome.

The sBLA is based on results from a phase II clinical trial with two treatment arms. One arm evaluated retreatment with ADCETRIS in patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse. The other arm allowed treatment extension and evaluated prolonged treatment with ADCETRIS beyond 16 cycles of therapy. The sBLA submission includes updated data sets from this phase II trial. Preliminary data from this trial were previously reported at the 2011 American Society of Hematology (ASH) Annual Meeting and at the 2012 American Society of Clinical Oncology (ASCO) Annual meeting.

At the 2012 ASCO Annual Meeting, retreatment data from the phase II trial were reported from 23 patients, including one patient who was treated twice. Patients had received a median of four prior systemic therapies, including ADCETRIS. Of 23 evaluable patients, 70 percent (16 of 23) achieved an objective response after retreatment with ADCETRIS, including nine complete remissions and seven partial remissions. Median duration of retreatment objective response was 8.8 months. Among retreated HL patients, nine of 16 (56 percent) achieved an objective response. Among retreated sALCL patients, seven of eight (88 percent) achieved an objective response. The most common adverse events were peripheral neuropathy (46 percent), nausea (42 percent), fatigue (38 percent), diarrhea (33 percent) and fever (29 percent).

At the 2011 ASH Annual Meeting, prolonged treatment data were reported from 17 patients with a median duration of treatment of 17.3 months (approximately 24 cycles of every three week dosing). The overall objective response rate with extended treatment was 88 percent, including 76 percent complete remissions and 12 percent partial remissions. ADCETRIS was generally well-tolerated, with the most common adverse events being peripheral neuropathy (71 percent), upper respiratory infection (53 percent) and fatigue (47 percent). Prolonged treatment with ADCETRIS was associated with clinically meaningful durations of response without worsening of toxicity over time.

ADCETRIS is currently not approved for retreatment and extended duration beyond 16 cycles of therapy in relapsed HL and sALCL.

About Lymphoma

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that also expresses CD30.

About ADCETRIS

Go here to see the original:
Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS® ...

Recommendation and review posted by Bethany Smith

By Carol Davis

PUBLISHED: 19:49 EST, 18 March 2013 | UPDATED: 19:49 EST, 18 March 2013

A new form of gene therapy could help thousands with an inherited eye condition that leads to blindness and possibly treat age-related macular degeneration and glaucoma.

Nick Tuftnell, 36, an IT consultant from Bristol, was the third in the world to have the operation.

'Over the next few years, my peripheral vision became worse,' said Nick Tuftnell

My grandfather was partially sighted, so Ive always known eye disease runs in the family. I remember having to watch out for him when I was younger.

When I was a teenager rushing to a cricket match at Lords, I forgot to warn him about a kerb, so he tripped.

But because my vision was fine, I didnt worry about myself too much until I was 17 and wanted my driving licence.

To check I could see properly, and aware of my family history, my ophthalmologist referred me to the specialist my grandad saw at Moorfields Eye Hospital in London.

Although my vision was fine, the specialist confirmed what wed suspected that like my grandad, I had choroideremia.

View post:
Eye condition: Injecting a virus into my eye saved my sight

Recommendation and review posted by Bethany Smith

BOSTON - A unique new cancer treatment uses gene therapy to induce a cancer-fighting immune response whose intensity can then be controlled with a pill. The combination could help tailor treatment to a patients individual response.

The treatment uses the bodys own cells or tumor cells to produce extra copies of a naturally occurring hormone-like molecule called IL-12, which regulates anticancer immune responses. Last week, Ziopharm Oncology announced a clinical study of the treatment for patients with breast cancer. The company is already testing it in patients with melanoma.

Many researchers have explored techniques that rev up the natural response the body uses to detect and attack cancerous cells (see, for example, Engineering Better Immune Cells and Priming the Body to Tackle Cancer). But controlling the killer cells of the immune system can sometimes be a challenge, as researchers found in the 1990s when cancer patients who were given IL-12 in a clinical trial died from toxic side effects.

IL-12 is a very potent [immune system regulator] and can generate a lot of side effects, says Per Basse, a physician-scientist at the University of Pittsburgh School of Medicine, who studies immune cells and their ability to fight cancer. As a clinician, I would like to be able to dial it up and down so that if it all starts to look not so good, you can stop the process, he says.

To avoid the dangerous side of the molecule, Ziopharms system is designed to control IL-12 with a combined genetic and pharmaceutical switch. A virus is injected into the tumor to deliver the gene for IL-12. The gene starts out in off mode, so it doesnt actually produce any IL-12. To activate the gene, a patient has to take a pill that delivers another molecule. The advantage is that any patient who starts to experience nasty side effects from the IL-12 can stop taking the pill. If things go awry, you have an escape valve, says Ziopharms CEO, Jonathan Lewis.

The key to the inducible system is a version of the receptor that controls molting in arthropods (insects, spiders, and crustaceans), modified so that it determines whether the IL-12 gene is on. The gene for that receptor, which is also delivered into the body by a virus, is always on, but its protein product and thus IL-12 expression is activated by the pill. Ziopharm licensed the control system from Intrexon for use in its oncology treatment.

The inducibility is a great idea, but the trick is getting something that you can get into the tumor, says Ralph Weichselbaum, a cancer researcher at the University of Chicago, who has worked on a cancer therapy induced by radiation. Currently, Ziopharm injects the gene-toting virus directly into patients tumors, but Lewis says the plan is to inject it into muscles in the future. Muscle cells are extremely good protein production factories, he says.

But even injecting the virus into a single tumor has an effect on other tumorsboth in lab animals and in humans. In animal studies, the tumor that receives the injection will at first get bigger because immune cells are accumulating in response to the IL-12. Then it will get smaller and go away, says Lewis. Tumors that received no injection will do the same thinggrow, then shrink, and then disappear. We are seeing similar things in people, says Lewis.

Eventually, the system could be used to deliver multiple genetic treatments at once, says Lewis. With one injection you could be able to control three or four [cancer-fighting] proteins in different ways.

Read the rest here:
Cancer gene therapy activated by a pill provides personalized treatment

Recommendation and review posted by Bethany Smith

Osmosis | Osmosis Skin Care | Cell Therapy
http://www.skincarebyalana.com/osmosis.html Alana interviews osmosis pur medical skin care cell therapy.

By: Alana Mitchell

See more here:
Osmosis | Osmosis Skin Care | Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Osmosis | Osmosis Skin Care | ATP Cell Therapy
Osmosis | Osmosis Skin Care | ATP Cell Therapy. Uploaded by Alana Mitchell on Mar 14 2013. httpwwwskincarebyalanacomosmosishtml Alana interviews osmosis pur medical skin care founder about ATP Cell Therapy.

By: Alana Mitchell

Read this article:
Osmosis | Osmosis Skin Care | ATP Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Stewart Brand: The dawn of de-extinction. Are you ready?
Throughout humankind #39;s history, we #39;ve driven species after species extinct: the passenger pigeon, the Eastern mountain lion, the dodo .... But now, says Stew...

By: TEDtalksDirector

Excerpt from:
Stewart Brand: The dawn of de-extinction. Are you ready? - Video

Recommendation and review posted by Bethany Smith

March 18, 2013, 3 a.m.

There was no doubt in Chontell Johnson's mind. When a genetic test revealed her mother had early onset Alzheimer's, the then-27-year-old decided she would get tested, too.

''If I didn't know, I would spend the rest of my life second-guessing decisions,'' she says.

The results confirmed that within the three billion letters of Johnson's genome, a single mistake means she has a 98 per cent chance of developing the neurological condition that killed her mother at 47.

''It scares the life out of me to think I'll not be able to communicate with people,'' says Johnson, now 33.

When the human genome was first sequenced 13 years ago, it was hailed as a medical revolution, the catalyst for this new era of personalised medicine.

For most of the past decade, however, genetic testing remained an expensive tool for research laboratories only.

But in recent years, the technology to read a person's genome has advanced at a staggering pace. Now a vial of spit or blood and an internet connection is all anybody needs to peer inside their body's blueprint.

But while labs can sequence a person's DNA in a couple of days for less than $1000 - compared with the original human genome project, which took a decade and cost more than $2 billion - interpreting a person's 23,000 or so genes into something meaningful for their future health has proved much more complex.

In a small fraction of diseases, such as cystic fibrosis, Huntington's disease and early onset familial Alzheimer's, genetic mutations are the direct cause. If you have the mutation (or mutations), there is no escaping the disorder.

Go here to see the original:
Living with a time bomb

Recommendation and review posted by Bethany Smith

Call Girl
When the Griffins find themselves in a financial bind, Lois is forced to find a job of her own. She gets discovered by a "voiceover" talent agent named Randy...

By: FHEFoxNetworkTV

Original post:
Call Girl - Video

Recommendation and review posted by Bethany Smith

Fukushima Symposium: Spent Fuel~An After Thought?
HELEN CALDICOTT FOUNDATION FUKUSHIMA SYMPOSIUM: 3-12-13 The Medical and Ecological Consequences of the Fukushima Nuclear Accident. Session Chair: Andrew Kant...

By: jrae50021

Excerpt from:
Fukushima Symposium: Spent Fuel~An After Thought? - Video

Recommendation and review posted by Bethany Smith

DNA 12/03/2013 #1603; #1604; #1606; #1575; #1604; #1581; #1586; #1576; #1575; #1604; #1604; #1607; ...
http://www.facebook.com/FutureTvPrograms http://www.future.com.lb/ http://www.twitter.com/futuretvnews.

By: futureprogramstv4

Read more:
DNA 12/03/2013 كلنا لحزب الله ... - Video

Recommendation and review posted by Bethany Smith

Dr. Wladimir Wertelecki - "Congenital Malformations in Rivne Polossia and Chernobyl Accident" [1/3]
"Congenital Malformations in Rivne Polossia and the Chernobyl Accident" by Dr. Wladimir Wertelecki (Former Chair of the Department of Medical Genetics, Unive...

By: dubbelschnubbel

More:
Dr. Wladimir Wertelecki - "Congenital Malformations in Rivne Polossia and Chernobyl Accident" [1/3] - Video

Recommendation and review posted by Bethany Smith

Dr. Wladimir Wertelecki - "Congenital Malformations in Rivne Polossia and Chernobyl Accident" [3/3]
"Congenital Malformations in Rivne Polossia and the Chernobyl Accident" by Dr. Wladimir Wertelecki (Former Chair of the Department of Medical Genetics, Unive...

By: dubbelschnubbel

Excerpt from:
Dr. Wladimir Wertelecki - "Congenital Malformations in Rivne Polossia and Chernobyl Accident" [3/3] - Video

Recommendation and review posted by Bethany Smith

If your genes revealed you would get a disease, would you want to know?
A massive, groundbreaking new study underway at Kaiser Permanente and the University of California San Francisco may shed light one day on the genetic roots ...

By: PBSNewsHour

Originally posted here:
If your genes revealed you would get a disease, would you want to know? - Video

Recommendation and review posted by Bethany Smith

The infamous and ingenious Ho Chi Minh Trail - Cameron Paterson
View full lesson: http://ed.ted.com/lessons/the-infamous-and-ingenious-ho-chi-minh-trail-cameron-paterson The Ho Chi Minh Trail not only connected North and ...

By: TEDEducation

See the rest here:
The infamous and ingenious Ho Chi Minh Trail - Cameron Paterson - Video

Recommendation and review posted by Bethany Smith

FIVE POINTS, Calif., March 17, 2013 /PRNewswire/ -- S&W Seed Company (SANW) today announced that it has agreedtopurchase 100% ofSeed Genetics InternationalPty Ltd("SGI"), subject to due diligence and other customary conditions.The combination of S&W with Adelaide, Australia-based SGI will create the world 's largest non-dormant alfalfa seed company. The transaction, which is valued at approximately $16 million, is scheduled to close in early April 2013 and is expected to be immediately accretive to S&W's earnings.

Mark Grewal, president and chief executive officer of S&W Seed Company, commented, "This pact creates a powerhouse that will be unrivaled in its ability to breed and produce non-dormant alfalfa seed all year round.SGI has a tremendous base of contracted growers, very strong customer relationships, andunique genetics.The sales channels that S&W and SGI sell into are highly complementary,with very little overlap in customers. This move considerably strengthens our reach into Argentina and the rest of Latin America."

Grewal added, "I also want to stress the 'people factor.'S&W is gaining a highly competitive team of veteran seedsmen whom we know well and highly respect. We look forward to collaboration with them in all areas. By putting growers first, SGI's breeding program, initiated by Dr. Ross Downes and now continued by David Pengelly, has created grower-focused varieties that produce more seed per acre for the seed farmer than any other varieties in Australia, adding to seed farmer profits and potentially lowering cost of seed for S&W. We have the opportunity to merge David's work with that of S&W's own VP of Genetics and Breeding, Dan Gardner and our emeritus breeder,Bob Sheesley, who himself did pioneering work in salt tolerance and seed yield."

S&W is paying a purchase price ofapproximately $16million, over half of which consists of 865,000 shares S&W Common Stock and will result in SGI's owners becoming significant shareholders of S&W. The remaining considerationconsists of $5million in cash and$3million in the form of athree-yearpromissory note.Based on unaudited information, SGI hadrevenues of approximately AUD $18million for the fiscal year ended June 30, 2012 andhadpre-tax income of$1.6 million. SGI's assets consist primarily of accounts receivable, inventory, a tenured grower base and intellectual property, such as genetics.S&W intends to file audited financial resultsofSGIno later than 74 daysfrom closing,in compliance with SEC guidelines.

SGIcontrols approximately17,000 acres of irrigated alfalfa seed production under contract, and has first call on another 12,000acres of non-irrigated land that is rain dependent and has intermittent production. Australian seed yields per acre, even on irrigated fields, typically are materially lower than S&W's California yields and production costs are also materially lower.In 2013, SGIcontracted for alfalfa seed production with approximately 140contractfarmersin Southern Australia, all for SGI's proprietary varieties.In fiscal 2012, SGI's growers producedapproximately 5.5 million pounds, concluding a growing season that suffered from the impact of highly adverse weather conditions. The 2013 harvest is currently ongoing, but based on initial estimates, SGI managementis estimating that it will have approximately 8million pounds of alfalfa seed available for sale when the harvest concludes in late April 2013. Actual production could vary materially in either direction from estimates, due to unforeseen weather events and other factors.

SGIsells intointernational markets, includingthe Middle East and Africa (MENA), South America, and Southern Europe with the majority of the company's sales concentrated in the April through September time frame.

SGI was founded in 2002, with the goal of commercializing a seed breeding breakthrough by Dr. Ross Downes. Working with alfalfa in the mid 1990's, Dr. Downes had identified a particular trait that resulted in dramatically increased seed yields, even with less than optimum pollinator activity. The intellectual property stemming from Dr. Downes' pioneering work, which has been protected under international law and the Australian Plant Breeders Rights Act, became the cornerstone for over a decade of development by SGI's David Pengelly. SGI has developed well known proprietary varieties, such asSuperSonic, SuperNova, SuperStar, SuperCharge, SuperAurora, SuperSequal and SuperSiriver. Starting in 2002, the varieties developed by SGI quickly attracted a grower base that by 2012 enabled SGIto exceed 60%of Australian alfalfa seed production.SGI'salfalfa seed varieties are bred to resist disease, have tolerance to salt, create persistence in the field, and produce high seed yields in Australian production.The company also has a number of developments within its breeding program pertaining to dormant alfalfa varieties, tropical alfalfa seed varieties, and ease of pollination.

SGI, like S&W, considers the goodwill of its seed grower base to be of premier importance. SGI's contracts with seedfarmers under long term contracts that typically have initial terms of six years, extendable to ten years. To manage risk for itself and its growers, seed pricing is not fixed by contract, but instead based upon pooled production which is sold over an entire season, with a view to optimizing the prices realized. Due to its Southern Hemisphere location,SGIharvests seed in March through April, which is counter cyclical to S&W's July through October production in the Northern Hemisphere. The combined company will have the competitive advantages of year round production, which extends to all areas of the alfalfa seed business, including sales, inventory management and cash collection cycles.

Mark Harvey,Directorof Seed Genetics International, commented, "First, my thanks to S&W's Chairman, Grover Wickersham, and S&W's CFO, Matt Szot, for their long visits to Australia and their patience in negotiating over the last half year. While this is obviously a big move for us, the directors and management of SGI are trulyexcited about the advantages of a combined S&W/SGI and we want the challenge of continuing to build on what the four partners started."

Mr. Harvey expanded, "For our Australian growers, this means we willbeexpanding production under the umbrella of a public company with a strong balance sheet and financial resources. We also gain access to S&W's proven proprietary genetics. We look forward to collaborating with S&W's well respected breeder, Dan Gardner, who is well known by our own David Pengelly and Ross Downes. When we learned last year that Dan and our tough and respected sales and marketing competitor from IVS, Fred Fabre, had both joined S&W, it piqued ourinterest."

Read more:
S&W Seed Company To Acquire Seed Genetics International

Recommendation and review posted by Bethany Smith

Professor Dinggang Li, M.D. - gene therapy, Gendicine
Professor Dinggang Li md gene therapy Gendicine. Uploaded by Danni ElKher on Mar 14 2013. Itroduction of the hospitals of Phoenix Hosiptal Group Beijing Health Palace Hospital and Beijing Yanhua Phoenix Hospital with Professor Dinggang Li md in front Gene therapy also known as Gendicine has been proven to be very useful in the fight against cancer Scandinavian patients wwwkirurgirejserdk. Plu Mb 69.

By: Danni El-Kher

See the rest here:
Professor Dinggang Li, M.D. - gene therapy, Gendicine - Video

Recommendation and review posted by Bethany Smith

Patients can turn off an experimental treatment if side effects get too bad.

A unique new cancer treatment uses gene therapy to induce a cancer-fighting immune response whose intensity can then be controlled with a pill. The combination could help tailor treatment to a patients individual response.

The treatment uses the bodys own cells or tumor cells to produce extra copies of a naturally occurring hormone-like molecule called IL-12, which regulates anticancer immune responses. Last week, Ziopharm Oncology announced a clinical study of the treatment for patients with breast cancer. The company is already testing it in patients with melanoma.

Many researchers have explored techniques that rev up the natural response the body uses to detect and attack cancerous cells (see, for example, Engineering Better Immune Cells and Priming the Body to Tackle Cancer). But controlling the killer cells of the immune system can sometimes be a challenge, as researchers found in the 1990s when cancer patients who were given IL-12 in a clinical trial died from toxic side effects.

IL-12 is a very potent [immune system regulator] and can generate a lot of side effects, says Per Basse, a physician-scientist at the University of Pittsburgh School of Medicine, who studies immune cells and their ability to fight cancer. As a clinician, I would like to be able to dial it up and down so that if it all starts to look not so good, you can stop the process, he says.

To avoid the dangerous side of the molecule, Ziopharms system is designed to control IL-12 with a combined genetic and pharmaceutical switch. A virus is injected into the tumor to deliver the gene for IL-12. The gene starts out in off mode, so it doesnt actually produce any IL-12. To activate the gene, a patient has to take a pill that delivers another molecule. The advantage is that any patient who starts to experience nasty side effects from the IL-12 can stop taking the pill. If things go awry, you have an escape valve, says Ziopharms CEO, Jonathan Lewis.

The key to the inducible system is a version of the receptor that controls molting in arthropods (insects, spiders, and crustaceans), modified so that it determines whether the IL-12 gene is on. The gene for that receptor, which is also delivered into the body by a virus, is always on, but its protein product and thus IL-12 expression is activated by the pill. Ziopharm licensed the control system from Intrexon for use in its oncology treatment.

The inducibility is a great idea, but the trick is getting something that you can get into the tumor, says Ralph Weichselbaum, a cancer researcher at the University of Chicago, who has worked on a cancer therapy induced by radiation. Currently, Ziopharm injects the gene-toting virus directly into patients tumors, but Lewis says the plan is to inject it into muscles in the future. Muscle cells are extremely good protein production factories, he says.

But even injecting the virus into a single tumor has an effect on other tumorsboth in lab animals and in humans. In animal studies, the tumor that receives the injection will at first get bigger because immune cells are accumulating in response to the IL-12. Then it will get smaller and go away, says Lewis. Tumors that received no injection will do the same thinggrow, then shrink, and then disappear. We are seeing similar things in people, says Lewis.

Eventually, the system could be used to deliver multiple genetic treatments at once, says Lewis. With one injection you could be able to control three or four [cancer-fighting] proteins in different ways.

See the rest here:
A Cancer Gene Therapy Activated by a Pill

Recommendation and review posted by Bethany Smith

TEDMED Great Challenges: The Future of Personalized Medicine
You need Adobe Flash Player to watch this video. Download it from Adobe. TEDMED Great Challenges The Future of Personalized Medicine. Catherine Andrews18 videos. SubscribeSubscribedUnsubscribe 36. Like. Sign in to youtube. Sign in with your youtube Accountyoutube Google+ Gmail Orkut Picasa or Chrome to like Catherine Andrewss video. Sign in. I dislike this. Sign in to youtube. Sign in with your youtube Accountyoutube Google+ Gmail Orkut Picasa or Chrome to dislike Catherine Andrewss ...

By: Catherine Andrews

Read more:
TEDMED Great Challenges: The Future of Personalized Medicine - Video

Recommendation and review posted by sam

Smallpox was eradicated completely in 1980. The only known stocks of the virus that causes smallpox are in carefully guarded laboratories in the U.S. and Russia. Nevertheless, the U.S. government is spending nearly $500 million for about two million doses of smallpox vaccine, according to a recent article in the New York Times.

Does this make sense? Well, yes and no. No one knows for sure whether there are unreported stocks of the virus somewhere, and if there are, whether they might fall into the wrong hands. Apparently the U.S. government thinks that it would be prudent to have a stock of smallpox vaccine on hand, just in case the smallpox virus is used someday in a bioterrorism attack.

Only time will tell whether stockpiling smallpox vaccine will prove to be a $500 million waste of money or a lifesaver. But while you’re considering whether you think it’s a good idea, consider this; if there is an outbreak of smallpox some day, who will be able to get the vaccine? Two million doses wouldn’t cover even a quarter of the population of New York City alone. How much of this vaccine should we be stockpiling?Source:
http://humanbiologyblog.blogspot.com/2013/03/stockpiling-smallpox-vaccine_14.html

Recommendation and review posted by Bethany Smith

Cell Therapy for Myeloma and Lymphoma by Dr Larry Kwak
Dr Larry Kwak, Professor and Chair of the department of Myeloma and Lymphoma at MD Anderson Cancer Center, Houston gave an update on the progress in cell the...

By: TheMedalGroup

The rest is here:
Cell Therapy for Myeloma and Lymphoma by Dr Larry Kwak - Video

Recommendation and review posted by Bethany Smith

Cell Therapy for Allogeneic Stem Cell Transplant by Dr Richard Champlin
Dr Richard Champlin, Professor and Chair of the department of Stem Cell Transplant and Cellular Therapy gave an update on the role of Cell Therapy in improvi...

By: TheMedalGroup

Read more:
Cell Therapy for Allogeneic Stem Cell Transplant by Dr Richard Champlin - Video

Recommendation and review posted by Bethany Smith